Suchergebnisse - "Moreau, Philippe"

PubPharm (119)

1

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

enthalten in: The New England journal of medicine | 2024

von Sonneveld, P. | Dimopoulos, M. | Boccadoro, M. | +141

CommentIn: N Engl J Med. 2024 Apr 18;390(15):1440. - PMID 38631009

2

Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma : Updated IKEMA Subgroup Analysis

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Kawano, Y. | Kim, K. | Min, C. | +13

3

Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO) : extended follow up of an open-label, randomised, multicentre, phase 3 trial

enthalten in: The Lancet. Haematology | 2023

von Dimopoulos, M. | Terpos, E. | Boccadoro, M. | +18

4

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

enthalten in: The New England journal of medicine | 2023

von San-Miguel, J. | Dhakal, B. | Yong, K. | +40

5

Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma : updated results from IKEMA, a randomized Phase 3 study

enthalten in: Blood cancer journal | 2023

von Martin, T. | Dimopoulos, M. | Mikhael, J. | +18

ErratumIn: Blood Cancer J. 2023 Sep 27;13(1):152. - PMID 37752114

6

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

enthalten in: The New England journal of medicine | 2023

von Rodriguez-Otero, P. | Ailawadhi, S. | Arnulf, B. | +19

CommentIn: Nat Rev Clin Oncol. 2023 Apr;20(4):210. - PMID 36849555

7

Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX) : A Randomized, Open-Label, Phase III Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Dimopoulos, M. | Oriol, A. | Nahi, H. | +19

8

Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma : IKEMA Subgroup Analysis by Prior Transplantation

enthalten in: Transplantation and cellular therapy | 2023

von Martin, T. | Capra, M. | Mohty, M. | +11

9

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma : Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Dimopoulos, M. | Dytfeld, D. | Grosicki, S. | +13

CommentIn: J Clin Oncol. 2023 Mar 20;41(9):1788. - PMID 36626704

10

Isatuximab plus carfilzomib and dexamethasone in Japanese patients with relapsed multiple myeloma : subgroup analysis of the randomized, open label, phase 3 IKEMA study

enthalten in: Japanese journal of clinical oncology | 2022

von Ishida, T. | Ito, S. | Tanaka, J. | +8

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[12]